Studies have demonstrated that CDKN2B is deleted in a wide spectrum of tumors including melanoma, pancreatic adenocarcinoma, glioblastoma, certain leukemias, non-small cell lung cancer, and bladder carcinoma (Kim and Sharpless, 2006). Here, CDKN2B is linked to non-small cell lung carcinoma.